Incorporated on gallium on July 31, 2007
-- A program continues on an improved oral formulation of the antiviral
compound acyclovir with a pharmaceutical company outside of the United
-- Satiety and oral glucose challenge studies for both GLP-1 and PYY will
be undertaken later this year at University Hospital, Switzerland
-- Parathyroid hormone continues on a progressive clinical development
path in collaboration with Novartis Pharma AG
Emisphere has 11 products in preclinical development:
-- Six projects with partners in obesity, osteoporosis, infectious disease
-- Five pre-clinical projects are in development without established
collaborations for a variety of therapeutic areas
-- Following completion of these pre-clinical projects, decisions would
then be taken to possibly proceed into future collaborations with each
of the partners for further pre-clinical or clinical development;
projects without established collaborations will be assessed for
continued development to the next step with or without a partner
"The technology that we are developing has proven to provide a solution that improves the delivery of existing molecules and treatment modalities. It also has an equally important application to new molecular entities where use may be restricted due to poor bioavailability," said Michael V. Novinski, President and Chief Executive Officer of Emisphere Technologies, Inc. "We are seeking to move our patented technology into a broad array of disease states and we anticipate the ability to dramatically increase the quality of life of a multitude of people."
About Emisphere Technologies, Inc.
Emisphere Technologies, Inc. is a biopharmaceutical company that
focuses on a unique and improved delivery of therapeutic molecules and
pharmaceutical compounds using its eligen
|SOURCE Emisphere Technologies, Inc.|
Copyright©2007 PR Newswire.
All rights reserved